McLean Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

McLean Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$210K	Buy	+272	New	+$208K	0.04%	162
2024 Q4	–	Sell	-263	Closed	-$266K	–	164
2024 Q3	$266K	Hold	263	–	–	0.08%	130
2024 Q2	$282K	Sell	263 -99	-27%	-$96K	0.09%	117
2024 Q1	$342K	Buy	362 +1	+0.3%	+$951	0.12%	97
2023 Q4	$330K	Sell	361 -3	-0.8%	-$2.47K	0.12%	90
2023 Q3	$304K	Hold	364	–	–	0.12%	93
2023 Q2	$262K	Sell	364 -1	-0.3%	-$771	0.1%	106
2023 Q1	$300K	Sell	365 -4	-1%	-$3.02K	0.12%	93
2022 Q4	$266K	Buy	369 +4	+1%	+$2.95K	0.09%	104
2022 Q3	$264K	Buy	365 +9	+3%	+$5.67K	0.1%	95
2022 Q2	$212K	Sell	356 -3	-0.8%	-$1.95K	0.08%	119
2022 Q1	$251K	Buy	359 +9	+3%	+$5.69K	0.19%	102
2021 Q4	$221K	Sell	350 -56	-14%	-$34.4K	0.09%	123
2021 Q3	$240K	Hold	406	–	–	0.09%	115
2021 Q2	$237K	Buy	+406	New	+$206K	0.11%	99
2021 Q1	–	Sell	-414	Closed	-$200K	–	106
2020 Q4	$200K	Buy	+414	New	+$223K	0.18%	94

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

McLean Asset Management's REGN Position: Q1 2026 in Review

McLean Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 272 shares worth $210K. The stake represents 0.04% of the portfolio and ranks #162 among its holdings. This is a return to the name: McLean Asset Management previously reported a position in REGN as recently as Q3 2024.

McLean Asset Management first reported a position in REGN in Q4 2020 and has held it in 16 quarters since. The position peaked at $342K in Q1 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

McLean Asset Management held 272 shares of Regeneron Pharmaceuticals worth $210K as of Q1 2026.
Regeneron Pharmaceuticals was a new McLean Asset Management position in Q1 2026.
Regeneron Pharmaceuticals made up 0.04% of McLean Asset Management's portfolio in Q1 2026, its #162 holding.
McLean Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
McLean Asset Management's Regeneron Pharmaceuticals position peaked at $342K in Q1 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on McLean Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.